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Abstract
Background:  Opitz G/BBB syndrome is a genetic disorder characterized by developmental
midline abnormalities, such as hypertelorism, cleft palate, and hypospadias. The gene responsible
for the X-linked form of this disease, MID1, encodes a TRIM/RBCC protein that is anchored to the
microtubules. The association of Mid1 with the cytoskeleton is regulated by dynamic
phosphorylation, through the interaction with the α4 subunit of phosphatase 2A (PP2A). Mid1 acts
as an E3 ubiquitin ligase, regulating PP2A degradation on microtubules.
Results: In spite of these findings, the biological role exerted by the Opitz syndrome gene product
is still unclear and the presence of other potential interacting moieties in the Mid1 structure
prompted us to search for additional cellular partners. Through a yeast two-hybrid screening
approach, we identified a novel gene, MIG12, whose protein product interacts with Mid1. We
confirmed by immunoprecipitation that this interaction occurs in vivo and that it is mediated by the
Mid1 coiled-coil domain. We found that Mig12 is mainly expressed in the neuroepithelial midline,
urogenital apparatus, and digits during embryonic development. Transiently expressed Mig12 is
found diffusely in both nucleus and cytoplasm, although it is enriched in the microtubule-organizing
center region. Consistently with this, endogenous Mig12 protein is partially detected in the
polymerized tubulin fraction after microtubule stabilization. When co-transfected with Mid1, Mig12
is massively recruited to thick filamentous structures composed of tubulin. These microtubule
bundles are resistant to high doses of depolymerizing agents and are composed of acetylated
tubulin, thus representing stabilized microtubule arrays.
Conclusions: Our findings suggest that Mig12 co-operates with Mid1 to stabilize microtubules.
Mid1-Mig12 complexes might be implicated in cellular processes that require microtubule
stabilization, such as cell division and migration. Impairment in Mig12/Mid1-mediated microtubule
dynamic regulation, during the development of embryonic midline, may cause the pathological signs
observed in Opitz syndrome patients.
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Background
Opitz syndrome (OS) is a congenital disorder affecting
primarily midline structures (MIM 145410 and 300000).
OS patients usually present with facial anomalies, includ-
ing hypertelorism and cleft lip and palate. OS also
includes laryngo-tracheo-esophageal (LTE), cardiac, and
genitourinary abnormalities. These symptoms show high
variability even within the same family [1-5]. OS is a het-
erogeneous disease with an X-linked (Xp22.3) and an
autosomal locus (22q11.2) [6]. The gene responsible for
the X-linked form, MID1, has been identified [7]. In male
OS patients, mutations have been found scattered
throughout the entire length of the MID1 gene, suggesting
a loss of function mechanism at the basis of this develop-
mental phenotype. Females carrying a mutated MID1
allele usually show only hypertelorism, likely as the result
of differential X-inactivation [7-11]. Interestingly, during
embryonic development the murine and avian orthologs
of the MID1  gene show an expression pattern that,
although not highly restricted, correlates with the tissues
affected in OS. Within these tissues, the mouse and chick
Mid1  transcripts are preferentially enriched in areas of
active proliferation [12,13]. Recently, the chick Mid1 gene
has been shown to be involved in the Sonic Hedgehog
pathway during the establishment of the molecular left/
right asymmetry in early embryonic avian development
[14].
MID1 encodes a protein belonging to the tripartite motif
family and is composed of a RING domain, two B-Box
domains, a coiled-coil region, together forming the tripar-
tite motif, followed by a fibronectin type III (FNIII) and
an RFP-like domain [7,15,16]. The tripartite motif family,
also known as TRIM or RBCC, comprises multi-domain-
proteins involved in the definition of cellular compart-
ments [17]. Mid1 self-interacts and forms high molecular
weight complexes that are anchored to the microtubules
throughout the cell cycle [18,19]. The most frequent
MID1 alterations found in OS patients affect the C-termi-
nal portion of the protein. Mutants that reproduce these
mutations show an altered microtubule association
[9,18,19]. The association of the wild-type protein with
microtubules is dynamic and is regulated by its phospho-
rylation status: dephosphorylation of Mid1, upon interac-
tion with the α4 regulatory subunit of phosphatase 2A
(PP2A) [20], displaces Mid1 from microtubules [21,22]. It
has also been reported that Mid1 functions as an E3 ubiq-
uitin ligase, regulating the microtubular PP2A catalytic
subunit degradation upon interaction with α4. PP2A deg-
radation, in turn, controls the phosphorylation status of
yet to be identified microtubule-associated-proteins
(MAPs) [23].
We have identified a novel Mid1 interacting protein
through yeast two-hybrid screening. This novel protein is
expressed in the midline during development and co-
operates with Mid1 to stabilize the microtubules.
Results
Identification of Mig12 as a novel Mid1 partner
To date, insights on the function of Mid1 in the cell have
emerged from its interaction with the α4 subunit of phos-
phatase 2A (PP2A), however, the role of Mid1 in the
pathogenesis of OS is still undetermined [21-24]. To get
clues on possible biological function of Mid1, we
searched for additional partners by screening a fibroblast
two-hybrid library. MidM, a construct encompassing the
C-terminal half of MID1, was used as a bait. This region,
which comprises the coiled-coil, the FNIII repeats and the
RFP-like domain of MID1, appears to be involved in the
anchorage to microtubules [9,18,19]. We obtained 6 pos-
itive clones, three of which were of different lengths,
belonging to a unique transcript. The largest fragment had
an ORF of 514 bp, the shortest of 432 bp. We used BLAST
http://www.ncbi.nlm.nih.gov/BLAST against the nr and
EST databases and we found perfectly matching clones
covering an ORF of 546 bp. We derived the complete
sequence from the deposited transcripts and amplified the
entire cDNA. We performed an interaction-mating assay
to confirm the binding. Both the full-length and the larg-
est original clone obtained from the library specifically
interact with the entire Mid1 protein (MidA) (Fig. 1A). We
also found positive interaction with portions of the Mid1
protein: MidD (coiled-coil), MidH (RING-B-boxes-
Coiled-coil) and with MidM, the construct used to screen
the library. No interaction was observed with MID1 con-
structs that lack the coiled-coil region (MidF and MidC,
Fig. 1A). The identified clone does not interact with other
members of the TRIM family (TRIM19/PML, TRIM25/
RFP, TRIM29/ATDC) that share structural homology with
Mid1 [17] (data not shown).
The full-length sequence matches with various anony-
mous human (hypothetical protein STRAIT11499,
NM_021242; FLJ10386, AK001248) and mouse
(AL671335, AK090003, and NM_026524 RIKEN) com-
plete cDNA sequences and several ESTs in the databases.
The human gene is located in Xp11.4 and is composed of
two exons, one of which encompasses the entire coding
region. The mouse gene is located in the A1.1 region of the
X chromosome. The human (GenBank accession no.
BK001260) and mouse (GenBank accession no.
AY263385) cDNAs encode a 182- and a 181-residue-pro-
tein, respectively, displaying no known domains with the
exception of a low score coiled-coil region at the C-termi-
nus of the protein. This Mid1 interactor records the high-
est homology with the zebrafish 'Gastrulation specific
protein G12' (NP_571410), a protein with unknown
function [25], and with the mammalian SPOT-14
(NM_003251), a protein involved in the metabolism ofBMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/9
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Identification of a novel Mid1 partner. Figure 1
Identification of a novel Mid1 partner. (A) Interaction-mating assay that confirms Mid1-Mig12 interaction in yeast. B42 fl, Mig12 
full-length fused to the B42 activation domain; B42 or, the largest original Mig12 clone fused to the B42 activation domain; 
LexA Mid, constructs encompassing different MID1 domains fused to the LexA DNA binding domain: A, full-length; C, BB; D, 
CC; F, RFP-like; H, R-BB-CC; M, CC-FNIII-RFP-like. Both the full-length and the original Mig12 clones specifically interact with 
the entire Mid1 protein and with some of its truncated mutants, MidD, MidH and MidM, as shown by yeast turning blue on X-
gal plates and growing on plates lacking leucine (Leu), only when galactose (Gal), and not glucose (Glu), is used as carbon 
source. Abbreviations: BB, B-box1 and B-box2 domains; CC, coiled-coil domain; FNIII, fibronectin type III repeat; R, RING 
domain. (B) Amino acid sequence of human (h) and mouse (m) MIG12 and comparison with the zebrafish G12 and the human 
SPOT14 proteins. Amino acids that are identical at least in the human and murine Mig12 are in bold. Conserved amino acids 
are indicated in gray. The human and mouse MIG12 share 90% of similarity and 88% of identity. The hMIG12 and the zebrafish 
protein share 56% of similarity and 46% of identity, whereas the homology with the human SPOT-14 protein is 49% and 31%, 
respectively. There is a gap of 25 aa that are not present in the zebrafish and SPOT14 proteins. (C) Co-immunoprecipitation 
experiments showing Mid1-Mig12 interaction. Western blot (WB) analysis using anti-Mid1 and anti-HA antibodies after immu-
noprecipitation of HEK293 cells transiently transfected with different combination of MycGFP-tagged Mid1 (MGFP-MID1) and 
an HA-tagged Mig12 (HA-MIG12); + and - indicate the constructs transfected in each lane. The antibodies used for the immu-
noprecipitations (IP) are indicated. Mid1 indicates the band corresponding to the endogenous protein. Ig, immunoglobulins. In 
some experiments, we detected a trace amount of MGFP-Mid1 immunoreactivity in cells transformed with only MGFP-Mid1 
and immunoprecipitated with the anti-HA antibody. This signal was always much less than that seen when both tagged con-
structs were transfected together. (D) The same as in (C) using the MGFP-MidM, MGFP-MidH and MGFP-MidD mutant 
fusions, instead of the full-length protein, in the co-transfections and an anti-Myc antibody for Western blot analysis.
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fatty acids [26,27]. The novel transcript was dubbed
MIG12 for Mid1 interacting G12-like protein, after the
similarity with the Danio rerio protein. Figure 1B shows
the alignment of the human and mouse Mig12, the
zebrafish G12, and the human SPOT14 proteins.
To confirm that the two proteins also interact in vivo, we
transiently transfected a MycGFP-tagged version of MID1
(MGFP-Mid1) and an HA-tagged version of MIG12 (HA-
Mig12) in HEK293 cells and immunoprecipitated using
either anti-Mid1 or anti-HA antibodies. Immunoprecipi-
tation of Mid1 in the co-transfected sample pulls down
the HA-Mig12 protein (right panel) and, vice versa, the
immunoprecipitation of Mig12 using the anti-HA anti-
body pulls down the MGFP-Mid1 protein (left panel)
(Fig. 1C). An unrelated polyclonal antibody and a differ-
ent anti-tag monoclonal antibody (anti-FLAG) did not
pull down the two proteins (data not shown), confirming
the specificity of Mid1-Mig12 interaction. Moreover,
Mig12 transfected alone is also pulled down by immuno-
precipitation of the endogenous Mid1 protein (Fig. 1C).
The interaction mating experiments suggest that the
coiled-coil region of Mid1 is necessary and sufficient for
the binding to Mig12. MGFP tagged versions of MidM,
MidH, and MidD were co-transfected with HA-MIG12 in
HEK293 cells and immunoprecipitated with either anti-
Myc or anti-HA antibodies. The three constructs, all
encompassing the coiled-coil region, are able to bind
Mig12 further confirming that, also in vivo, this region is
sufficient for Mid1-Mig12 interaction (Fig. 1D).
Mig12 is mainly expressed in the developing CNS midline
Since Mid1 is implicated in a developmental disorder, to
support a physiologically relevant interaction between
Mig12 and Mid1 we analyzed the mRNA expression of
Mig12 during embryonic development. The Mig12 clone
originally obtained from the two-hybrid screening was
used as a probe to perform mRNA in situ hybridization on
mouse embryos at several embryonic stages. A ubiquitous
expression pattern was found both on section and in
whole mount experiments from embryonic day 9.5 (E9.5)
up to E11.5. At E11.5, we detected a diffuse staining in the
central nervous system (CNS) and a more restricted signal
in the developing limbs by whole-mount in situ hybridi-
zation (Fig. 2A, a). An even more restricted expression pat-
tern is observed at E14.5 when high transcript levels are
detected in specific compartments (Fig. 2A, b). The strong-
est expression is observed in the developing central nerv-
ous system and is particularly evident in the coronal
sections through the hindbrain region (Fig. 2B, a–c). The
signal is observed in the neuroepithelium of the cerebellar
primordia (Fig. 2B, a,b), of the pons (Fig. 2B, a, b, e), and
of the medulla oblongata (Fig. 2B, c). The ventricular
hindbrain signal is mainly confined to the ventral midline
(Fig. 2B, a, b, c). This medial expression is maintained
throughout the central canal of the spinal cord extending
through the floor and roof plates (Fig. 2B, d). In the telen-
cephalon, Mig12 signal is present in the ventricular zone
of the telencephalic vesicles (Fig. 2B, f). Within the nerv-
ous system, Mig12 transcript is also detected in the dorsal
roots and in the trigeminal ganglia (Fig. 2A, b; 2B, d). At
this stage, expression of Mig12 is also observed in several
additional organs. The transcript is observed in the inter-
digital web in both the developing hind- and forelimbs at
E11.5 (Fig. 2A, a). At E14.5, as the development of the
limbs proceeds, Mig12 transcript is detected in the peri-
chondrium of the digits (Fig. 2B, g). The other organs
expressing Mig12 include the left and right thyroid lobes
and the parathyroid glands (Fig. 2B, h); the phallic part of
the urogenital sinus (Fig. 2B, i); the anal canal (rectum)
and the epithelium lining the lumen of the bladder (data
not shown). Interestingly, many of the sites that show
high Mig12 levels also express the Mid1 transcript [12,13]
and are affected in OS patients [5,11].
Mid1 recruits Mig12 on the microtubules
Transient expression of either MGFP- or HA-tagged Mig12
reveals a diffuse distribution of the protein in Cos7 as well
as in other cell lines (U2OS, HeLa, NIH3T3). To exclude a
tag-driven mislocalization, we also transfected a non-
tagged version of Mig12: the specific anti-Mig12 antibody
reveals a distribution comparable to that of the tagged ver-
sions. Mig12 is present in both the nucleus and the cyto-
plasm and the relative abundance in the two
compartments is variable (Fig. 3A).
Mid1 is associated with microtubules during the entire
cell cycle [18,19]. An example of its distribution is shown
in figure 3B (arrow, upper panel), where Mid1 co-local-
izes with the normal radial interphase microtubules.
Interestingly, when co-expressed in the same cell, Mid1
and Mig12 form bundles within the cytoplasm (Fig. 3B).
Mig12 usually also maintains a diffused distribution
whose extent depends on its expression level. As shown in
the lower panels, the observed bundles show variable
thickness and shape that depend on the expression levels
of the two proteins. Nevertheless, these bundles are only
present when the two proteins are co-expressed. In our
experimental conditions we do not observe the formation
of bundles in cells transfected with only Mid1 (Fig. 3B,
arrow). The co-localization of Mid1 and Mig12 within the
bundles has been confirmed by confocal microscopy anal-
ysis (Fig. 3C).
We investigated the distribution of Mig12 in cells co-
transfected with mutant Mid1 proteins that are not
anchored to the microtubules. Mid1 C-terminal OS
mutants localize to cytoplasmic bodies [9,18,19]. These
mutant forms, that retain the coiled-coil region, are able
to recruit Mig12 within these structures (Fig. 3D, upperBMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/9
Page 5 of 12
(page number not for citation purposes)
panels). The same is observed using a construct that drives
the expression of only the coiled-coil domain of Mid1
(Fig. 3D, middle panels). This recruitment is not observed
when other TRIM proteins, that share the same domain
composition of Mid1, are expressed with Mig12. This is
demonstrated by co-transfections of Mig12 with TRIM19/
PML (Fig. 3D, lower panels), TRIM5 or TRIM27 (data not
shown). These results confirm that Mid1, through its
coiled-coil domain, is able to specifically recruit Mig12 to
different structures within the cell.
Since Mid1 is a microtubular protein, we asked whether
the bundles observed in cells co-expressing Mig12 and
Mid1 are structures of microtubular nature. Co-localiza-
tion of tubulin with the bundles, in immunofluorescence
experiments, demonstrates that these structures are micro-
tubule arrays rearranged by overexpression of the two pro-
teins and that are often present as continuous or
fragmented perinuclear rings (Fig. 4A).
To confirm these data, we performed microtubule sedi-
mentation after taxol treatment in cells co-transfected
with both Mid1 and Mig12. After fractionation on a
sucrose cushion, the supernatant and the pellet contain-
ing the polymerized tubulin were assayed by immunoblot
for the presence of both proteins. Mig12 and Mid1 are
recovered in the pellet, where tubulin is also found.
Mig12, as expected, is also present in the supernatant. This
result further indicates that the bundles observed in
immunofluorescence experiments are of microtubular
nature (Fig. 4B, left panel). A control protein that does not
associate with the microtubules, spastin ∆ N [28], is not
present in the microtubule fraction, confirming that the
presence of Mig12 in the pellet is not due to contamina-
tion during the sedimentation process (data not shown).
Moreover, the presence of Mig12 in the pellet, as well as
that of tubulin, is lost when the cells are not treated with
the microtubule stabilization agent, taxol (data not
shown). Thus, when overexpressed, Mid1 and Mig12 have
the ability to rearrange interphase radial microtubules
into these structures.
Interestingly, singly transfected Mig12 also partially sedi-
ments with the microtubular pellet, as expected to a lesser
extent than the double transfectant (Fig. 4B, right panel).
Since the affinity purified anti-Mig12 antibody we pro-
duced allows the specific detection of the endogenous
protein in immunoblot experiments in cell line lysates, as
shown in figure 4C, we carried out sedimentation of
polymerized microtubules in HeLa cells to test the pres-
ence of endogenous Mig12 in the microtubule pellet.
These results indicate that the protein, likely by interacting
with endogenous Mid1 protein, is at least partially associ-
ated with microtubules (Fig. 4D). A closer look at some
single transfected cells reveals indeed a partial co-localiza-
tion of Mig12 with the microtubules, also in the absence
of exogenous Mid1 (Fig. 4E). Some filaments are observed
over the diffuse staining and in many cells enrichment of
Mig12 expression analysis during embryonic development. Figure 2
Mig12 expression analysis during embryonic development. 
(A) Whole mount in situ hybridization on E11.5 mouse 
embryo showing expression in the central nervous system 
and in the developing limbs (blue signal, a). Coronal and sagit-
tal sections of E14.5 entire mouse embryos (white signal) (b).  
(B) Details of coronal (a, b, c, d, h) and sagittal (e, f, g, i) sec-
tions of E14.5 mouse embryos. Strong Mig12 expression (red 
signal) is observed in isthmal (a), pontine (a, b, e) and medulla 
oblongata (c) neuroepithelia, and it is maintained throughout 
the entire region of the spinal cord central canal (d). Expres-
sion is also observed in dorsal root ganglia (d). Mig12 tran-
script is detected in the telencephalon at the level of the 
ventricular zone (f). Signal is also present in other organs: in 
the perichondrium of the digits (g); in the thyroid (th) and 
parathyroid (pth) glands (h), and in the phallic part of the 
urogenital sinus (i). Abbreviations: CB, cerebellum; ccn, cen-
tral canal neuroepithelium; drg, dorsal root ganglia; IS, isth-
mus; isn, isthmal neuroepithelium; M, medulla oblongata; mn, 
medulla oblongata neuroepithelium; P, pons; pc, perichon-
drium; pnn, pontine neuroepithelium; pth, parathyroid glands; 
SC, spinal cord; T, telencephalon; th, thyroid gland; us, uro-
genital sinus; vz, ventricular zone.BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/9
Page 6 of 12
(page number not for citation purposes)
Immunofluorescence analyses reveal co-localization of Mid1 and Mig12 within the cell. Figure 3
Immunofluorescence analyses reveal co-localization of Mid1 and Mig12 within the cell. (A) Immunofluorescence analysis after 
transient expression of MGFP-Mig12 (upper panel), HA-Mig12 (middle panel) and untagged Mig12 (lower panel) in Cos7 cells, 
revealing a diffuse distribution of the protein, in both the nucleus and the cytoplasm. (B) Co-expression of both Mid1 and 
Mig12 leads to co-localization of the two proteins in cytoplasmic bundles. Standard fluorescence microscopy shows formation 
of bundles only in Mid1 (left panels) and Mig12 (right panel) co-expressing cells. The arrow indicates a single transfected cell 
where Mid1 shows the classical distribution along normal interphase microtubules. (C) The co-localization is confirmed by 
confocal microscopy analysis in which HA-Mid protein is visible as a red signal and MGFP-Mig12 protein as a green signal; co-
localization is indicated as a yellow signal in merged images. (D) Co-localization is also observed using the HA-Mig12 construct 
(middle panels) together with either a Mid1 OS truncated mutant (GFP-Mid1 1331insA) or a Mid1 mutant (GFP-MidD) retain-
ing the coiled-coil domain, both localized in cytoplasmic bodies. No co-localization is observed when HA-TRIM19/PML protein 
is co-expressed with GFP-Mig12. The right panels represent the merged images.
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Mid1 and Mig12 co-sediment with microtubules. Figure 4
Mid1 and Mig12 co-sediment with microtubules. (A) Immunofluorescence analysis in Cos7 cells co-transfected with HA-Mid1 
(left panels) and MGFPMig12 (middle panel) proteins. Coincidence of the bundles with microtubules is revealed using mono-
clonal antibodies against β-tubulin (right panel). These images show the different thickness and distribution of the bundles. (B) 
Cos7 cells were transfected with either MGFPMid and HA-Mig12 (left panel) or HA-Mig12 alone (right panel). Lysates (L) from 
cells were supplemented with 40 µM taxol to stabilize polymerized microtubules. After sedimentation on sucrose cushion, 
supernatant (S) and pellet (P) fractions were assayed for the presence of Mid1, Mig12, and tubulin using appropriate antibodies. 
In the co-transfection (left panel) both Mid1 and Mig12 were detected in the pellet together with the polymerized microtu-
bules. As expected Mig12 is also present in the soluble fraction where neither Mid1 nor the tubulin are found. Mig12 is found 
partially associated with the polymerized tubulin fraction also in the single HA-Mig12 transfected cells (right panel). (C) West-
ern blot analysis using the anti-Mig12 antibody reveals a 24 KDa protein in two different cell lines lysates (1, Cos7; 2, HeLa 
cells). To confirm specificity, incubation with the primary antibody was also performed in the presence of either the fusion pro-
tein used to immunize rabbits (GST-Mig12) or an unrelated fusion protein (GST-ur). (D) Detection of endogenous Mig12 in 
the polymerized microtubule fraction (+ taxol) in HeLa cells and as control in the non-treated sample (-taxol); legend as in (A). 
(E) Single Mig12 transfected Cos7 cells show partial localization with microtubules, particularly in the MTOC region (upper 
panels) and at the mitotic spindle poles (lower panels).
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Mig12 protein in the MTOC region is evident (Fig. 4E,
upper panels) as well as partial co-localization with the
mitotic spindle (Fig. 4E, lower panels).
Mid1 and Mig12 induce stable microtubule bundles
To better understand the nature of these microtubule
arrays, we asked what happens to the Mid1-Mig12
bundles upon disruption of the microtubular architec-
ture. Cells were co-transfected and exposed to nocoda-
zole, a microtubule-depolymerizing agent, for 1 hour
before fixation and then analyzed by immunofluores-
cence. The filaments observed after overexpression of the
two proteins were more resistant to the drug compared to
control microtubules (Fig. 5A). In contrast, cells overex-
pressing only Mid1 show complete disruption of the
microtubular apparatus, which is consistent with the
absence of bundles (Fig. 5A, arrow). Partial disruption of
the Mid1-Mig12 bundles was observed only after longer
exposure to nocodazole (4 h, data not shown).
Modification of tubulin subunits by acetylation marks
older microtubules and therefore indicates those that are
more stable [29]. Specific antibodies to acetylated tubulin
decorate the Mid1-Mig12 induced nocodazole-resistant
bundles, thus indicating stable microtubules (Fig. 5B).
The ability to stabilize the microtubules is not a character-
istic of cells overexpressing Mig12 alone: in fact, treatment
with nocodazole does not reveal any residual microtubu-
lar structures in these cells (data not shown).
These data suggest that Mig12 co-operates with Mid1 to
stabilize microtubules. The Mid1-Mig12 microtubule-sta-
bilizing effect might be implicated in specific processes
during the development of the midline systems that are
affected in Opitz syndrome patients.
Discussion
The role of the Opitz syndrome gene product, Mid1, in the
pathogenesis of this human disorder is still unclear
[14,24]. We now present data that support a role of Mid1
in the regulation of microtubule dynamics. We report the
identification of a novel gene, MIG12, that encodes a
Mid1 interacting protein. MIG12  shares high sequence
homology with a zebrafish gene product, the 'gastrulation
protein G12', which is expressed in a narrow window of
time during D. rerio gastrulation [25]. A Mig12 paralog in
mammals, SPOT14, is a nuclear protein that responds to
the thyroid hormone and regulates lipid synthesis
[26,27]. However, the mechanism of action for both G12
and SPOT14 is still unknown. Further, the absence of rec-
ognizable domains in its peptide sequence does not allow
any a priori hypothesis on MIG12 function to be drawn.
The expression pattern of Mig12 during embryonic devel-
opment is consistent with that of Mid1  [12,13].
Furthermore, this pattern overlaps with tissues whose
development is defective in OS [5,9,11]. The strong
expression in the midline of the developing central nerv-
ous system might be related to the neurological signs
found in a high number of patients that manifest agenesis
or hypoplasia of the corpus callosum and of the cerebellar
vermis, and mental retardation. Moreover, expression of
Mig12 in the rostral medial CNS could also be involved in
the determination of proper craniofacial formation. It is
well known that factors expressed in the CNS midline are
implicated in resolving a single eye field into two lateral
fields, an event that determines the head midline width
and the face traits as reviewed in [30,31]. One of these,
Sonic hedgehog (Shh), plays a crucial role in the ventral
midline neural tube patterning and regulates the morpho-
genesis of a variety of midline and lateral organs. It is
interesting to note the recent association of the Mid1 gene
and the Shh pathway in the early midline and laterality
specification in the chicken [14]. Interference with the
correct Mig12-Mid1 pathway might be responsible for the
craniofacial defects observed in OS. Expression in the
embryonic urogenital and anal apparatus is also reminis-
cent of defects observed in OS, hypospadias and imperfo-
rate or ectopic anus. In addition, we can parallel the inter-
digit Mig12 expression observed in the mouse embryos
with OS manifestations, as we observed syndactyly in a
MID1-mutated patient [11]. The low frequency of muta-
tions in MID1 and the high variability of the phenotype in
OS patients suggest the involvement of other genes in the
OS phenotype. It is plausible that other proteins involved
Mid1 and Mig12 together stabilize the microtubules. Figure 5
Mid1 and Mig12 together stabilize the microtubules. (A) 
Nocodazole treatment does not disrupt the Mid1/Mig12 gen-
erated bundles of tubulin, whereas it disrupts the microtu-
bules in Mid1 single transfected cells (arrow). (B) The 
bundles represent stable microtubules as demonstrated by 
perfect coincidence with the anti-acetylated tubulin antibody 
signal (blue).
A
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B
MID1 MIG12
MID1 MIG12 Ac TUBULINBMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/9
Page 9 of 12
(page number not for citation purposes)
in the Mid1 pathway are implicated in the heterogeneity
of OS (or in other syndromes showing clinical overlap
with OS) and Mig12 might well be a candidate.
When Mig12 is over-expressed, it barely decorates micro-
tubules with a signal almost imperceptible due to its dif-
fused distribution in the cytoplasm. Accordingly,
endogenous Mig12 is partially found associated with the
polymerized tubulin fraction in cell lysates. Interestingly,
when co-expressed with Mid1 it induces the formation of
microtubule bundles. This effect is not observed when
Mid1 is expressed alone. Mid1 specifically recruits Mig12
to the microtubules and the consequent induction of bun-
dles could be explained by the propensity of both pro-
teins, Mid1 [18] and Mig12 (CB, GM, unpublished
results), to homo-interact. The formation of multimers
might tether a high number of microtubule interacting
moieties that, in turn, mediate and favor the association
of parallel microtubule arrays. The shape and location of
these microtubule bundles is variable within the cell: peri-
nuclear rings, sub-cortical bundles and a roundish mass in
the MTOC region. In some cases, we also observed frag-
mentation of these thick microtubular structures (CB,
GM, unpublished results) that might suggest the involve-
ment of a putative microtubule severing activity [32].
These microtubule bundles are resistant to depolymeriz-
ing agents, such as nocodazole, and are composed of
acetylated tubulin and therefore represent stable microtu-
bules. This bundling and stabilizing effect has been
observed for other microtubule binding proteins, in par-
ticular microtubule-associated-proteins (MAPs) and other
proteins involved in mitotic spindle organization, cytoki-
nesis and the control of cell motility such as, PRC1,
NuMA, CLASPs, and many others [33-36]. It is worth not-
ing that recently two proteins sharing homology with the
C-terminal half of Mid1, Mir1 and GLFND that have a
coiled-coil-FNIII-RFP-like structure, have been shown to
bundle and stabilize microtubules [37,38]. So far, we have
no indications on the behavior of Mid1-Mig12 complexes
during mitosis. Mid1 decorates the mitotic spindle [18]
and Mig12, when transfected alone, appears to be both
associated with the spindle poles and diffused within the
cell. We have never observed mitotic cells overexpressing
both proteins. Whether this is due to interference with the
division process is still to be clarified.
The bundling effect observed in our over-expression sys-
tem probably reflects a weaker and finely tuned-regulated
process in physiological conditions. The shuttling of
Mig12 between nucleus and cytoplasm might also be
dynamically regulated and, in certain conditions, segrega-
tion in the nucleus might be necessary to prevent interfer-
ence with the interphase microtubule network. Mid1
might recruit Mig12 to microtubules only when needed. It
is possible that phosphorylation of Mid1 [21,22] and/or
putative post-translational modifications of Mig12 might
regulate their physiological association and the subse-
quent stabilization of the microtubule network. The ulti-
mate aim of the regulation of microtubule stability and
dynamics involving the Mid1-Mig12 pathway is still to be
elucidated and may be connected to cell cycle progression
or cell migration, events known to require microtubule
stabilization [39]. Alteration of either process can be seen
as possible causes of pathological signs in OS. Mig12, as
well as Mid1, appears to be preferentially expressed in
highly proliferating embryonic fields (e.g., the ventricular
zone of the developing brain). Nevertheless, these are also
cells that, after mitosis has been completed, are
committed to migrate. The zebrafish gastrulation protein
G12 is expressed in a restricted lineage characterized by
extensive cell migration [25]; it is tempting to speculate
that this process could be the one implicated in the patho-
genesis of the Opitz syndrome.
Conclusions
We have reported the identification of a novel Opitz syn-
drome gene product interacting protein, Mig12, that co-
operates with Mid1 to stabilize microtubules. These data
are consistent with the role of Mid1 in microtubule
dynamics. Mid1, in fact, controls MAP phosphorylation
through the regulation of PP2A microtubular levels [23]
and Mig12 may participate in this pathway. During
embryonic development of midline structures, impair-
ment in Mid1-Mig12-mediated microtubule dynamics
regulation might be detrimental and lead to Opitz
syndrome.
Methods
Plasmid constructs
The  MID1  expression vectors MycGFP-MID1 and HA-
MID1 have already been reported [18]. The MID1 dele-
tion mutants, MidC, MidD, MidF, MidH, and MidM have
been excised from HA-pCDNA3 vectors [18] and cloned
EcoRI/XhoI in the two-hybrid vectors pJG4-5 and pEG202
[40]. Full-length MIG12  cDNA was generated by PCR
amplification, using specific primers designed on ESTs
sequences, from NIH3T3 total RNA as template. The PCR
product was then cloned into EcoRI and XhoI sites in the
eukaryotic expression vectors pcDNA3, pcDNA3-MGFP
and pcDNA3-HA. Both Myc-GFP and HA tags are posi-
tioned at N-terminus region of MIG12 coding region. Full-
length MIG12 was also cloned in the pJG4-5 two-hybrid
vector fused to the B42 activation domain [40].
Yeast two-hybrid screening
The two-hybrid screening was performed using MIDM
(CC-FNIII-RFP-like) cloned in pEG202 vector that con-
tains the LexA DNA-binding domain. The bait was trans-
formed into the yeast strain EGY48 that was subsequently
transformed with an NIH3T3 cDNA library cloned intoBMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/9
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pJG4-5, containing the B42 activation domain. Trans-
formants (5 × 106 independent clones) were seeded on
plates containing either X-gal or lacking Leucine to select
positive clones that have activated both LexA driven
reporter genes (lacZ and LEU2). Interaction mating assay
to confirm the positivity was performed using the same
system and two different yeast mating types (EGY48 MAT
α and EGY42 MAT a) as described [40].
Cell culture and transfection
Monkey Kidney Cos-7 cells and HEK 293T cells were cul-
tured in Dulbecco's modified Eagle's medium, supple-
mented with 10% fetal bovine serum, at 37°C in a 5%
CO2 atmosphere. All transfections were carried out by cal-
cium phosphate precipitation [41]. In a typical transfec-
tion experiment 20 µg of expression vector were used per
15-cm dish. For immunofluorescence experiments, using
chamber-slides (8 wells, Nunc), 0.5 µg DNA/well were
transfected.
Immunoprecipitation, Immunoblot, and Antibodies
In co-immunoprecipitation experiments 4.5 × 106 HEK
293T cells per 15-cm dish were seeded. 60 h after transfec-
tion cells were collected, washed and extracted with RIPA
buffer (150 mM NaCl, 1% Igepal, 0.5% DOC, 0.1% SDS,
50 mM Tris-HCl pH 8) supplemented with protease
inhibitors (Roche). Extracts were sonicated and centri-
fuged at 10000 g for 10 min at 4°C to remove cell debris.
The supernatants were immunoprecipitated with either 6
µg of anti-HA antibody, 500 µl anti-Myc (9E10) hybrid-
oma supernatant or 8 µg anti-Mid1 polyclonal antibody
(H35) [18], for 3 h at 4°C and the immuno-complexes
collected with protein A-Sepharose beads for 30 min. The
beads were washed six times with RIPA buffer and pro-
teins eluted from the beads by boiling in SDS loading
buffer. Proteins were separated on either 10% or 12% SDS
PAGE and blotted onto PVDF membranes (Amersham).
The membranes were rinsed in methanol and blocked in
TTBS (20 mM Tris-HCl pH 7, 50 mM NaCl and 0.1%
Tween-20), 5% dry milk. Incubation with the primary
antibodies was performed using anti-c-Myc monoclonal
antibody (1:5 dilution), anti-HA monoclonal antibody
(Roche) (1:500 dilution) and anti-Mid1 polyclonal anti-
body (1:250 dilution) in TTBS, 5% dry milk. Antibody
binding was detected with a secondary anti-mouse or anti-
rabbit IgG coupled with horseradish peroxidase, followed
by visualization with the Enhanced Chemiluminescence
Kit (Amersham). A specific anti-Mig12 antiserum has
been raised against a full-length Mig12 protein fused to
GST and produced in bacteria. Affinity purification of the
antibody was performed with the GST-Mig12 covalently
attached to a CNBr-activated sepharose column using
standard procedures. To perform competition experi-
ments, 20 µg of the same protein were used to compete
the binding in immunoblot analysis. As non-specific com-
petitor, the same amount of an unrelated GST fusion pro-
tein (Mid1 RING domain) was used.
Immunofluorescence
Cos7 cells were grown on chamber-slides (8 wells, Nunc)
in DMEM, 10% FBS, and transfected as described. After 36
h, cells were fixed in 4% paraformaldehyde/PBS for 10
min at room temperature, permeabilized with 0.2% Tri-
ton X-100/PBS for 30 min, blocked with normal serum for
1 h and incubated for 3 h with the primary antibodies and
1 h with the appropriate secondary antibodies. The fol-
lowing primary antibodies were used: protein A-purified
polyclonal anti-Mid1 (1:200 dilution), monoclonal anti-
β-tubulin (1:250 dilution) (Molecular Probes), mono-
clonal anti-HA (CA25) antibody (1:250 dilution)
(Roche), monoclonal anti-acetylated tubulin (1:200 dilu-
tion) (Sigma). The following secondary antibodies were
used: fluorescein isothiocyanate (FITC)-conjugated anti-
rabbit antibodies alone or both tetramethylrhodamine
isothiocyanate (TRITC) conjugated anti-rabbit and FITC
conjugated anti-mouse-antibodies (1:100 dilution)
(Dako). For confocal microscopy, Cy3-conjugated anti-
mouse antibody was used (1:200 dilution) (Amersham).
When indicated, nocodazole in DMSO was added at the
final concentration of 40 µM for 1 h at 37°C before
fixation.
Microtubule binding assay
Cells were harvested either 48 hours post-transfection
(Cos7 cells) or when at 80% confluence (non-transfected
HeLa cells) and lysed in PEM-DNNA buffer (80 mM PIPES
pH 6.8, 1 mM EGTA, 1 mM MgCl2, 0.5 mM DTT, 150 mM
NaCl, 1% Igepal) supplemented with protease inhibitors,
at 4°C for 1 hr. The lysate was centrifuged at 610 g for 10
min at 4°C. Cytosol was then purified by successive cen-
trifugations at 10,000 g for 10 min, at 21,000 g for 20 min
and at 100,000 g for 1 hr at 4°C. Each supernatant was
then supplemented with 2 mM GTP (Roche) and 40 µM
taxol (Molecular Probes) and incubated at 37°C for 30
min. Corresponding samples without taxol were also pre-
pared. Each sample was layered over a 15% sucrose cush-
ion and centrifuged at 30,000 g for 30 min at 30°C to
sediment polymerized microtubules. The resulting super-
natants were saved and the pellets were suspended in an
equal volume of sample buffer for electrophoresis and
immunoblot analysis.
RNA in situ hybridization
One of the original clones obtained from the screening
(540 bp fragment whose 5' corresponds to nt 113 of the
MIG12 coding region) was linearized with the appropri-
ate restriction enzymes to transcribe either sense or anti-
sense  35S-labeled riboprobe. Mouse embryo tissue
sections were prepared and RNA in situ hybridization
experiments performed as previously described [42].BMC Cell Biology 2004, 5 http://www.biomedcentral.com/1471-2121/5/9
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Autoradiographs were exposed for 2 days. Slides were
then dipped in Kodak NTB2 emulsion and exposed for
14–21 days. In the micrographs red represents the hybrid-
ization signal and blue shows the nuclei stained with
Hoechst 33258 dye. Whole-mount in situ hybridization
was performed using the same probe and following the
protocol described in [43].
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